{ "data": { "id": "org_gsk", "slug": "gsk", "name": "GSK", "short_name": "GSK", "type": "company", "tier": 2, "homepage": "https://www.gsk.com", "country_code": "GB", "reliability_note": null, "url": "https://statorigin.org/sources/gsk", "documents": [ { "title": "GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK", "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok", "statistic_count": 4 }, { "title": "GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data", "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok", "statistic_count": 3 }, { "title": "GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences", "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-potential-best-in-class-t-cell-engager-tce-for-multiple-myeloma-from-chimagen-biosciences/", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok", "statistic_count": 1 }, { "title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok", "statistic_count": 20 } ], "statistics": [ { "id": "stat_P5RVAZ88DTFW4FMEP5VTP07QF2", "url": "https://statorigin.org/stat/stat_P5RVAZ88DTFW4FMEP5VTP07QF2", "indicator": { "slug": "biopharma-biotech-and-ai-companies-count", "name": "Biopharma, biotech and AI companies count", "definition": "Total count of operating biopharmaceutical, biotechnology, and artificial intelligence companies located within a cluster." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GB", "name": "United Kingdom", "type": "country" }, "period": { "start": "2026-07-28", "end": "2026-07-28", "type": "point" }, "value": 470, "value_text": "470", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/", "document_type": "press_release", "locator": "GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK", "quote": "More than 1 million patients are treated on the campus every year, and over 470 biopharma/ biotech and AI companies are located there.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/. Via StatOrigin, https://statorigin.org/stat/stat_P5RVAZ88DTFW4FMEP5VTP07QF2", "bibtex": "@misc{gsk2026biopharmap07qf2,\n author = {{GSK}},\n title = {GSK to establish new flagship R\\&D centre on Cambridge Biomedical Campus, UK},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_P5RVAZ88DTFW4FMEP5VTP07QF2},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_NSQAJK7CN21ZJ189AWWMCKY12P", "url": "https://statorigin.org/stat/stat_NSQAJK7CN21ZJ189AWWMCKY12P", "indicator": { "slug": "clinical-development-drug-pipeline-assets-count", "name": "Clinical development drug pipeline assets count", "definition": "Total count of active drug candidates in clinical development." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-07-28", "end": "2026-07-28", "type": "point" }, "value": 62, "value_text": "62", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "R&D acceleration:", "quote": "62 assets in clinical development with opportunities for significant growth", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_NSQAJK7CN21ZJ189AWWMCKY12P", "bibtex": "@misc{gsk2026clinicalcky12p,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_NSQAJK7CN21ZJ189AWWMCKY12P},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_HEV6X9524JMG0W909PSF771HMW", "url": "https://statorigin.org/stat/stat_HEV6X9524JMG0W909PSF771HMW", "indicator": { "slug": "core-operating-profit-growth-quarterly", "name": "Core operating profit growth (quarterly)", "definition": "Quarterly percentage change in core operating profit." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 7, "value_text": "+7%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth", "quote": "Core operating profit +7% and Core EPS +9% reflecting higher sales and favourable product and regional mix, partly offset by increased investment in R&D and new asset launches and lower royalty income", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_HEV6X9524JMG0W909PSF771HMW", "bibtex": "@misc{gsk2026core771hmw,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_HEV6X9524JMG0W909PSF771HMW},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_3CJAHW70FHY4DYTNB3P2GZ5NKN", "url": "https://statorigin.org/stat/stat_3CJAHW70FHY4DYTNB3P2GZ5NKN", "indicator": { "slug": "general-medicines-sales-growth-quarterly", "name": "General medicines sales growth (quarterly)", "definition": "Quarterly percentage growth rate of general medicines sales." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": -9, "value_text": "-9%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth", "quote": "General Medicines sales £2.3 billion (-9%); Trelegy £0.8 billion (-7%)", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_3CJAHW70FHY4DYTNB3P2GZ5NKN", "bibtex": "@misc{gsk2026generalgz5nkn,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_3CJAHW70FHY4DYTNB3P2GZ5NKN},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_8SG6BAH33KS8XBTTYZREJ61GP8", "url": "https://statorigin.org/stat/stat_8SG6BAH33KS8XBTTYZREJ61GP8", "indicator": { "slug": "general-medicines-sales-revenue-quarterly", "name": "General medicines sales revenue (quarterly)", "definition": "Quarterly sales revenue generated by the general medicines portfolio." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 2.3, "value_text": "£2.3 billion", "unit": "GBP", "currency": "GBP", "scale": "billion", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth", "quote": "General Medicines sales £2.3 billion (-9%); Trelegy £0.8 billion (-7%)", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_8SG6BAH33KS8XBTTYZREJ61GP8", "bibtex": "@misc{gsk2026generalj61gp8,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_8SG6BAH33KS8XBTTYZREJ61GP8},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_1BF9MV6SAFMQNAJG9K258MQC6J", "url": "https://statorigin.org/stat/stat_1BF9MV6SAFMQNAJG9K258MQC6J", "indicator": { "slug": "hiv-medicines-sales-growth-quarterly", "name": "HIV medicines sales growth (quarterly)", "definition": "Quarterly percentage growth rate of HIV drug sales." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 10, "value_text": "+10%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth", "quote": "Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £1.1 billion (+19%); Oncology £0.6 billion (+17%); HIV sales £2.1 billion (+10%)", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_1BF9MV6SAFMQNAJG9K258MQC6J", "bibtex": "@misc{gsk2026medicines8mqc6j,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_1BF9MV6SAFMQNAJG9K258MQC6J},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_JKTBXTE0ZE78YWJVFD85AT3NQY", "url": "https://statorigin.org/stat/stat_JKTBXTE0ZE78YWJVFD85AT3NQY", "indicator": { "slug": "hiv-medicines-sales-revenue-quarterly", "name": "HIV medicines sales revenue (quarterly)", "definition": "Quarterly sales revenue generated from HIV pharmaceuticals." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 2.1, "value_text": "£2.1 billion", "unit": "GBP", "currency": "GBP", "scale": "billion", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth", "quote": "Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £1.1 billion (+19%); Oncology £0.6 billion (+17%); HIV sales £2.1 billion (+10%)", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_JKTBXTE0ZE78YWJVFD85AT3NQY", "bibtex": "@misc{gsk2026medicinesat3nqy,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_JKTBXTE0ZE78YWJVFD85AT3NQY},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGGF", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGF", "indicator": { "slug": "influenza-cases", "name": "Influenza cases", "definition": "The estimated annual number of seasonal influenza cases worldwide." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-12-31", "type": "year" }, "value": 1, "value_text": "one billion cases", "unit": "count", "currency": null, "scale": "billion", "value_type": "estimate", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/", "document_type": "press_release", "locator": "About seasonal flu", "quote": "Seasonal influenza causes around one billion cases globally each year, including up to 5 million cases of severe illness and up to 650,000 respiratory deaths.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data. Retrieved September 15, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGF", "bibtex": "@misc{gsk2026influenzabjmggf,\n author = {{GSK}},\n title = {GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGF},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGGH", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGH", "indicator": { "slug": "influenza-deaths", "name": "Influenza deaths", "definition": "The estimated annual number of respiratory deaths caused by seasonal influenza worldwide." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-12-31", "type": "year" }, "value": 650000, "value_text": "650,000 respiratory deaths", "unit": "count", "currency": null, "scale": "1", "value_type": "estimate", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/", "document_type": "press_release", "locator": "About seasonal flu", "quote": "Seasonal influenza causes around one billion cases globally each year, including up to 5 million cases of severe illness and up to 650,000 respiratory deaths.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data. Retrieved September 15, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGH", "bibtex": "@misc{gsk2026influenzabjmggh,\n author = {{GSK}},\n title = {GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGH},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_HQSNWEB4WE3RP5NHCY3VNHYW9D", "url": "https://statorigin.org/stat/stat_HQSNWEB4WE3RP5NHCY3VNHYW9D", "indicator": { "slug": "life-sciences-employment", "name": "Life sciences employment", "definition": "Total number of individuals employed in the life sciences sector within a campus or designated cluster." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GB", "name": "United Kingdom", "type": "country" }, "period": { "start": "2026-07-28", "end": "2026-07-28", "type": "point" }, "value": 22000, "value_text": "22,000", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/", "document_type": "press_release", "locator": "GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK", "quote": "The Cambridge Biomedical Campus is home to more than 22,000 people working in life sciences, with more than 37,000 people visiting every day.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/. Via StatOrigin, https://statorigin.org/stat/stat_HQSNWEB4WE3RP5NHCY3VNHYW9D", "bibtex": "@misc{gsk2026lifenhyw9d,\n author = {{GSK}},\n title = {GSK to establish new flagship R\\&D centre on Cambridge Biomedical Campus, UK},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_HQSNWEB4WE3RP5NHCY3VNHYW9D},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_1V3Z865SSN2HW20Y3VVR25RJ76", "url": "https://statorigin.org/stat/stat_1V3Z865SSN2HW20Y3VVR25RJ76", "indicator": { "slug": "long-term-annual-sales-outlook", "name": "Long-term annual sales outlook", "definition": "Projected long-term annual sales revenue target." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2031-01-01", "end": "2031-12-31", "type": "year" }, "value": 40, "value_text": "£40 billion", "unit": "GBP", "currency": "GBP", "scale": "billion", "value_type": "forecast", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "Growth outlooks:", "quote": "On track for 2031 sales outlook of more than £40 billion; Accelerating growth from 2031 onwards", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2031). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_1V3Z865SSN2HW20Y3VVR25RJ76", "bibtex": "@misc{gsk2031long25rj76,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2031},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_1V3Z865SSN2HW20Y3VVR25RJ76},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_X2M3QDC0A8Q04AR0SZQKMS832B", "url": "https://statorigin.org/stat/stat_X2M3QDC0A8Q04AR0SZQKMS832B", "indicator": { "slug": "oncology-sales-growth-quarterly", "name": "Oncology sales growth (quarterly)", "definition": "Quarterly percentage growth rate of oncology product sales." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 17, "value_text": "+17%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth", "quote": "Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £1.1 billion (+19%); Oncology £0.6 billion (+17%); HIV sales £2.1 billion (+10%)", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_X2M3QDC0A8Q04AR0SZQKMS832B", "bibtex": "@misc{gsk2026oncologyms832b,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_X2M3QDC0A8Q04AR0SZQKMS832B},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_HS3TJF064M6Z2PQ2SKQK4VBC5A", "url": "https://statorigin.org/stat/stat_HS3TJF064M6Z2PQ2SKQK4VBC5A", "indicator": { "slug": "oncology-sales-revenue-quarterly", "name": "Oncology sales revenue (quarterly)", "definition": "Quarterly sales revenue generated from oncology therapeutics." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 0.6, "value_text": "£0.6 billion", "unit": "GBP", "currency": "GBP", "scale": "billion", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth", "quote": "Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £1.1 billion (+19%); Oncology £0.6 billion (+17%); HIV sales £2.1 billion (+10%)", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_HS3TJF064M6Z2PQ2SKQK4VBC5A", "bibtex": "@misc{gsk2026oncology4vbc5a,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_HS3TJF064M6Z2PQ2SKQK4VBC5A},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_1DN19V4QD824M3FEKW6YFSHYQ4", "url": "https://statorigin.org/stat/stat_1DN19V4QD824M3FEKW6YFSHYQ4", "indicator": { "slug": "operating-profit-growth-quarterly", "name": "Operating profit growth (quarterly)", "definition": "Quarterly percentage growth rate of total operating profit." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": -75, "value_text": "-75%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth", "quote": "Total operating profit -75% and Total EPS -69% driven by higher impairments, primarily related to camlipixant of £1.3 billion, and higher CCL charges, partly offset by Core operating profit growth and higher divestment income", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_1DN19V4QD824M3FEKW6YFSHYQ4", "bibtex": "@misc{gsk2026operatingfshyq4,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_1DN19V4QD824M3FEKW6YFSHYQ4},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_TV42FRJC8C1W7RGT6S3KBRANNY", "url": "https://statorigin.org/stat/stat_TV42FRJC8C1W7RGT6S3KBRANNY", "indicator": { "slug": "pharmaceutical-and-life-sciences-r-d-facility-investment", "name": "Pharmaceutical and life sciences R&D facility investment", "definition": "Total capital investment planned or committed to pharmaceutical and life sciences research and development facilities." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GB", "name": "United Kingdom", "type": "country" }, "period": { "start": "2026-07-28", "end": "2026-07-28", "type": "point" }, "value": 400, "value_text": "£400 million", "unit": "GBP", "currency": "GBP", "scale": "million", "value_type": "estimate", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/", "document_type": "press_release", "locator": "GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK", "quote": "£400 million investment in UK life sciences", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/. Via StatOrigin, https://statorigin.org/stat/stat_TV42FRJC8C1W7RGT6S3KBRANNY", "bibtex": "@misc{gsk2026pharmaceuticalbranny,\n author = {{GSK}},\n title = {GSK to establish new flagship R\\&D centre on Cambridge Biomedical Campus, UK},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_TV42FRJC8C1W7RGT6S3KBRANNY},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_MY9WRY1B7MTDECAMXEEJR98D29", "url": "https://statorigin.org/stat/stat_MY9WRY1B7MTDECAMXEEJR98D29", "indicator": { "slug": "pharmaceutical-and-life-sciences-r-d-facility-investment-annual", "name": "Pharmaceutical and life sciences R&D facility investment (annual)", "definition": "Total capital investment planned or committed to pharmaceutical and life sciences research and development facilities." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GB", "name": "United Kingdom", "type": "country" }, "period": { "start": "2026-07-28", "end": "2029-07-28", "type": "year" }, "value": 400, "value_text": "£400 million", "unit": "GBP", "currency": "GBP", "scale": "million", "value_type": "forecast", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/", "document_type": "press_release", "locator": "GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK", "quote": "Overall, the company plans to invest £400 million over 3 years in support of these changes.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2029). GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/. Via StatOrigin, https://statorigin.org/stat/stat_MY9WRY1B7MTDECAMXEEJR98D29", "bibtex": "@misc{gsk2029pharmaceuticalr98d29,\n author = {{GSK}},\n title = {GSK to establish new flagship R\\&D centre on Cambridge Biomedical Campus, UK},\n year = {2029},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_MY9WRY1B7MTDECAMXEEJR98D29},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_NAZF6DZ1XTDSKBY9NBTYVHJ7NE", "url": "https://statorigin.org/stat/stat_NAZF6DZ1XTDSKBY9NBTYVHJ7NE", "indicator": { "slug": "pharmaceutical-sales-revenue", "name": "Pharmaceutical sales revenue", "definition": "Total sales revenue generated from pharmaceutical and healthcare products." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 8.4, "value_text": "£8.4 billion", "unit": "GBP", "currency": "GBP", "scale": "billion", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth", "quote": "Total Q2 sales £8.4 billion +5% AER; +5% CER", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_NAZF6DZ1XTDSKBY9NBTYVHJ7NE", "bibtex": "@misc{gsk2026pharmaceuticalvhj7ne,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_NAZF6DZ1XTDSKBY9NBTYVHJ7NE},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_EMC7N66KBBH4AZRQ7SDVQXQ2WW", "url": "https://statorigin.org/stat/stat_EMC7N66KBBH4AZRQ7SDVQXQ2WW", "indicator": { "slug": "phase-iii-clinical-trial-starts-annual", "name": "Phase III clinical trial starts (annual)", "definition": "Number of phase III clinical trial initiations scheduled or started within a year." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-12-31", "type": "year" }, "value": 20, "value_text": "20+", "unit": "count", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "R&D acceleration:", "quote": "Now expect 20+ phase III trial starts in 2026 (previously 10)", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_EMC7N66KBBH4AZRQ7SDVQXQ2WW", "bibtex": "@misc{gsk2026phaseqxq2ww,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_EMC7N66KBBH4AZRQ7SDVQXQ2WW},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01DTKMTBK16STBNVA34DMFDTC6", "url": "https://statorigin.org/stat/stat_01DTKMTBK16STBNVA34DMFDTC6", "indicator": { "slug": "respiratory-immunology-and-inflammation-sales-growth-quarterly", "name": "Respiratory immunology and inflammation sales growth (quarterly)", "definition": "Quarterly percentage growth rate of respiratory, immunology, and inflammation pharmaceutical sales." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 19, "value_text": "+19%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth", "quote": "Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £1.1 billion (+19%); Oncology £0.6 billion (+17%); HIV sales £2.1 billion (+10%)", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_01DTKMTBK16STBNVA34DMFDTC6", "bibtex": "@misc{gsk2026respiratorymfdtc6,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01DTKMTBK16STBNVA34DMFDTC6},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_9113AJM3546SNR5D3R4PHH61H4", "url": "https://statorigin.org/stat/stat_9113AJM3546SNR5D3R4PHH61H4", "indicator": { "slug": "respiratory-immunology-and-inflammation-sales-revenue-quarterly", "name": "Respiratory immunology and inflammation sales revenue (quarterly)", "definition": "Quarterly sales revenue generated from respiratory, immunology, and inflammation pharmaceuticals." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 1.1, "value_text": "£1.1 billion", "unit": "GBP", "currency": "GBP", "scale": "billion", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth", "quote": "Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £1.1 billion (+19%); Oncology £0.6 billion (+17%); HIV sales £2.1 billion (+10%)", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_9113AJM3546SNR5D3R4PHH61H4", "bibtex": "@misc{gsk2026respiratoryhh61h4,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_9113AJM3546SNR5D3R4PHH61H4},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_STP49SCZRH9GEF2K3RK1JNDCJG", "url": "https://statorigin.org/stat/stat_STP49SCZRH9GEF2K3RK1JNDCJG", "indicator": { "slug": "sales-growth-at-actual-exchange-rates-quarterly", "name": "Sales growth at actual exchange rates (quarterly)", "definition": "Quarterly percentage growth rate of total sales evaluated at actual exchange rates." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 5, "value_text": "+5%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth", "quote": "Total Q2 sales £8.4 billion +5% AER; +5% CER", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_STP49SCZRH9GEF2K3RK1JNDCJG", "bibtex": "@misc{gsk2026salesjndcjg,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_STP49SCZRH9GEF2K3RK1JNDCJG},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_20FMSJFEMXAS09KAG9QFENHNMC", "url": "https://statorigin.org/stat/stat_20FMSJFEMXAS09KAG9QFENHNMC", "indicator": { "slug": "sales-growth-at-constant-exchange-rates-quarterly", "name": "Sales growth at constant exchange rates (quarterly)", "definition": "Quarterly percentage growth rate of total sales evaluated at constant exchange rates." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 5, "value_text": "+5%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth", "quote": "Total Q2 sales £8.4 billion +5% AER; +5% CER", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_20FMSJFEMXAS09KAG9QFENHNMC", "bibtex": "@misc{gsk2026salesenhnmc,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_20FMSJFEMXAS09KAG9QFENHNMC},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGGG", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGG", "indicator": { "slug": "severe-influenza-cases", "name": "Severe influenza cases", "definition": "The estimated annual number of severe illness cases caused by seasonal influenza worldwide." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-01-01", "end": "2026-12-31", "type": "year" }, "value": 5, "value_text": "5 million cases", "unit": "count", "currency": null, "scale": "million", "value_type": "estimate", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/", "document_type": "press_release", "locator": "About seasonal flu", "quote": "Seasonal influenza causes around one billion cases globally each year, including up to 5 million cases of severe illness and up to 650,000 respiratory deaths.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data. Retrieved September 15, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGG", "bibtex": "@misc{gsk2026severebjmggg,\n author = {{GSK}},\n title = {GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGG},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_Y9C44KZVB64QMXMM57PE3GJVW6", "url": "https://statorigin.org/stat/stat_Y9C44KZVB64QMXMM57PE3GJVW6", "indicator": { "slug": "specialty-medicines-sales-growth-quarterly", "name": "Specialty medicines sales growth (quarterly)", "definition": "Quarterly percentage growth rate of specialty medicines sales." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 14, "value_text": "+14%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth", "quote": "Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £1.1 billion (+19%); Oncology £0.6 billion (+17%); HIV sales £2.1 billion (+10%)", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_Y9C44KZVB64QMXMM57PE3GJVW6", "bibtex": "@misc{gsk2026specialty3gjvw6,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_Y9C44KZVB64QMXMM57PE3GJVW6},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_CYNAPQ76STC6DXDDWH3BKMXMCS", "url": "https://statorigin.org/stat/stat_CYNAPQ76STC6DXDDWH3BKMXMCS", "indicator": { "slug": "specialty-medicines-sales-revenue-quarterly", "name": "Specialty medicines sales revenue (quarterly)", "definition": "Quarterly sales revenue generated from specialty medicines." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 3.8, "value_text": "£3.8 billion", "unit": "GBP", "currency": "GBP", "scale": "billion", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth", "quote": "Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £1.1 billion (+19%); Oncology £0.6 billion (+17%); HIV sales £2.1 billion (+10%)", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_CYNAPQ76STC6DXDDWH3BKMXMCS", "bibtex": "@misc{gsk2026specialtykmxmcs,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_CYNAPQ76STC6DXDDWH3BKMXMCS},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGGE", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGE", "indicator": { "slug": "t-cell-engager-market-size-for-multiple-myeloma", "name": "T-cell engager market size for multiple myeloma", "definition": "Total market value of T-cell engagers for multiple myeloma." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2032-01-01", "end": "2032-12-31", "type": "year" }, "value": 10, "value_text": "$10 billion", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "forecast", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-potential-best-in-class-t-cell-engager-tce-for-multiple-myeloma-from-chimagen-biosciences/", "document_type": "press_release", "locator": "Deal aligned to GSK’s portfolio in blood cancer and approach of acquiring differentiated assets with validated targets", "quote": "The US TCE market for multiple myeloma is expected to exceed $10 billion by 2032.1", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2032). GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences. Retrieved September 15, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-potential-best-in-class-t-cell-engager-tce-for-multiple-myeloma-from-chimagen-biosciences/. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGE", "bibtex": "@misc{gsk2032cellbjmgge,\n author = {{GSK}},\n title = {GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences},\n year = {2032},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGE},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-potential-best-in-class-t-cell-engager-tce-for-multiple-myeloma-from-chimagen-biosciences/. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_Z2ZK6DF34K6V7K61SKEQ4AWAA6", "url": "https://statorigin.org/stat/stat_Z2ZK6DF34K6V7K61SKEQ4AWAA6", "indicator": { "slug": "vaccines-sales-growth-quarterly", "name": "Vaccines sales growth (quarterly)", "definition": "Quarterly percentage growth rate of vaccine sales." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 8, "value_text": "+8%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth", "quote": "Vaccines sales £2.3 billion (+8%); Shingrix £0.9 billion (+3%); Meningitis vaccines £0.5 billion (+21%); and Arexvy £0.2 billion (+>100%)", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_Z2ZK6DF34K6V7K61SKEQ4AWAA6", "bibtex": "@misc{gsk2026vaccines4awaa6,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_Z2ZK6DF34K6V7K61SKEQ4AWAA6},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_GP49QP0JN19KQN5Q0182XYSAPW", "url": "https://statorigin.org/stat/stat_GP49QP0JN19KQN5Q0182XYSAPW", "indicator": { "slug": "vaccines-sales-revenue-quarterly", "name": "Vaccines sales revenue (quarterly)", "definition": "Quarterly sales revenue generated from the vaccines portfolio." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "GLOBAL", "name": "Global", "type": "world" }, "period": { "start": "2026-04-01", "end": "2026-06-30", "type": "quarter" }, "value": 2.3, "value_text": "£2.3 billion", "unit": "GBP", "currency": "GBP", "scale": "billion", "value_type": "actual", "source": { "org": "GSK", "org_short_name": "GSK", "org_url": "https://www.gsk.com", "org_tier": 2, "document_title": "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026", "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/", "document_type": "press_release", "locator": "Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth", "quote": "Vaccines sales £2.3 billion (+8%); Shingrix £0.9 billion (+3%); Meningitis vaccines £0.5 billion (+21%); and Arexvy £0.2 billion (+>100%)", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_GP49QP0JN19KQN5Q0182XYSAPW", "bibtex": "@misc{gsk2026vaccinesxysapw,\n author = {{GSK}},\n title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_GP49QP0JN19KQN5Q0182XYSAPW},\n note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" } ] }, "meta": { "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.", "license": "https://creativecommons.org/licenses/by/4.0/", "docs": "https://statorigin.org/docs/api", "total": 28, "note": "Statistics are capped at 100 per request. Use /statistics?source_org=gsk with a cursor to page through everything." } }